Bank of New York Mellon Corp Trims Holdings in Intuitive Surgical, Inc. $ISRG

Bank of New York Mellon Corp lowered its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 8.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,123,290 shares of the medical equipment provider’s stock after selling 394,179 shares during the period. Bank of New York Mellon Corp owned approximately 1.15% of Intuitive Surgical worth $1,844,059,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Tobam boosted its holdings in shares of Intuitive Surgical by 666.7% in the 2nd quarter. Tobam now owns 46 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 40 shares during the last quarter. Kilter Group LLC purchased a new stake in Intuitive Surgical in the second quarter valued at $27,000. Princeton Global Asset Management LLC acquired a new stake in Intuitive Surgical during the 2nd quarter worth about $30,000. Riggs Asset Managment Co. Inc. raised its stake in shares of Intuitive Surgical by 84.2% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 70 shares of the medical equipment provider’s stock valued at $38,000 after buying an additional 32 shares during the last quarter. Finally, First Command Advisory Services Inc. lifted its holdings in shares of Intuitive Surgical by 3,750.0% in the 2nd quarter. First Command Advisory Services Inc. now owns 77 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 75 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of NASDAQ ISRG opened at $525.04 on Wednesday. The firm has a fifty day moving average of $561.53 and a 200 day moving average of $511.67. The firm has a market cap of $188.21 billion, a PE ratio of 66.55, a PEG ratio of 4.12 and a beta of 1.67. Intuitive Surgical, Inc. has a one year low of $425.00 and a one year high of $609.08.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.27 by $0.26. The business had revenue of $2.87 billion for the quarter, compared to analyst estimates of $2.72 billion. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. The company’s revenue for the quarter was up 18.8% compared to the same quarter last year. During the same quarter last year, the business earned $2.21 earnings per share. On average, equities analysts predict that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Intuitive Surgical News Roundup

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: TD Cowen initiated coverage with a Buy and a $660 target, citing the da Vinci 5 rollout and secular procedure growth as catalysts that could drive multi-year revenue and margin upside. TD Cowen initiates coverage
• Positive Sentiment: TD Cowen / TipRanks coverage note expands on the same thesis, highlighting da Vinci 5 rollout execution and secular procedure growth as underpinning a $660 target. TipRanks: TD Cowen Buy Rating
• Positive Sentiment: The FDA granted 510(k) clearance for the da Vinci 5 in select cardiac procedures, expanding the platform into more minimally invasive heart surgeries — a direct product/regulatory win that can support procedure growth and long-term consumable revenue. da Vinci 5 FDA clearance
• Positive Sentiment: HSBC raised its price target to $653 and maintained a Buy, reinforcing bullish analyst sentiment and implying meaningful upside from current levels. HSBC raises PT to $653
• Positive Sentiment: Barclays reiterated its Buy rating, another vote of confidence from the sell-side that supports investor sentiment. Barclays remains Buy
• Positive Sentiment: American Banking News reports a raised price target to $615, adding to the cluster of higher analyst targets that can support upside expectations. Price target raised to $615
• Neutral Sentiment: Interest in ISRG is high among retail/institutional investors (searches up), which can increase short-term volatility but does not by itself change fundamentals. Investors heavily search ISRG
• Negative Sentiment: Zacks highlights rising competitive pressure in China — slower tenders, local favoritism and pricing pressure — which could weigh on growth and margins in a key market if trends accelerate. China competition headwinds
• Negative Sentiment: Robert W. Baird trimmed its price target to $645 — a modest downgrade that could temper upside expectations even though the target remains above current levels. Baird cuts PT to $645

Wall Street Analysts Forecast Growth

Several research firms recently commented on ISRG. BTIG Research reaffirmed a “buy” rating and set a $616.00 target price on shares of Intuitive Surgical in a report on Friday, January 23rd. Jefferies Financial Group raised their price objective on shares of Intuitive Surgical from $550.00 to $560.00 and gave the stock a “hold” rating in a research note on Wednesday, October 22nd. Hsbc Global Res upgraded shares of Intuitive Surgical to a “strong-buy” rating in a research note on Thursday, October 23rd. Daiwa Capital Markets increased their price target on shares of Intuitive Surgical from $510.00 to $550.00 and gave the stock an “outperform” rating in a report on Friday, October 24th. Finally, Leerink Partners raised their price target on shares of Intuitive Surgical from $593.00 to $600.00 and gave the company an “outperform” rating in a research report on Wednesday, October 22nd. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $620.41.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, SVP Mark Brosius sold 464 shares of Intuitive Surgical stock in a transaction on Monday, December 15th. The shares were sold at an average price of $548.49, for a total transaction of $254,499.36. Following the sale, the senior vice president owned 131 shares of the company’s stock, valued at $71,852.19. The trade was a 77.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Gary S. Guthart sold 22,806 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $570.89, for a total transaction of $13,019,717.34. Following the completion of the sale, the insider owned 2,694 shares of the company’s stock, valued at $1,537,977.66. This trade represents a 89.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 48,027 shares of company stock worth $27,402,696 in the last quarter. Corporate insiders own 0.70% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.